Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Non-Cystic Fibrosis Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Non-Cystic Fibrosis Bronchiectasis: Overview
Non–cystic fibrosis (non-CF) bronchiectasis is a progressive respiratory disease characterized by a permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes. The symptoms and clinical course of NCFB are variable. Some patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily. The classic clinical manifestations of this clinical condition are cough and daily mucopurulent sputum production, often lasting months to years. Blood-streaked sputum or hemoptysis may result from airway damage associated with acute infection. Dyspnea and wheezing occur in 75% of patients. Pleuritic chest pain occurs in 50% of patients and reflects the presence of distended peripheral airways or distal pneumonitis adjacent to a visceral pleural surface. Physical examination of the chest shows adventitious breath sounds, such as crackles (70%), wheezing (34%) or rhonchi (44%).
'Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis pipeline landscape is provided which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis treatment guidelines. The assessment part of the report embraces, in depth Non-Cystic Fibrosis Bronchiectasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Non-Cystic Fibrosis Bronchiectasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non-Cystic Fibrosis Bronchiectasis Emerging Drugs
Further product details are provided in the report……..
Non-Cystic Fibrosis Bronchiectasis: Therapeutic Assessment
This segment of the report provides insights about the different Non-Cystic Fibrosis Bronchiectasis drugs segregated based on following parameters that define the scope of the report, such as:
Non-Cystic Fibrosis Bronchiectasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Cystic Fibrosis Bronchiectasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Cystic Fibrosis Bronchiectasis drugs.
Non-Cystic Fibrosis Bronchiectasis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Non-Cystic Fibrosis Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Non-Cystic Fibrosis Bronchiectasis: Overview
Non–cystic fibrosis (non-CF) bronchiectasis is a progressive respiratory disease characterized by a permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes. The symptoms and clinical course of NCFB are variable. Some patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily. The classic clinical manifestations of this clinical condition are cough and daily mucopurulent sputum production, often lasting months to years. Blood-streaked sputum or hemoptysis may result from airway damage associated with acute infection. Dyspnea and wheezing occur in 75% of patients. Pleuritic chest pain occurs in 50% of patients and reflects the presence of distended peripheral airways or distal pneumonitis adjacent to a visceral pleural surface. Physical examination of the chest shows adventitious breath sounds, such as crackles (70%), wheezing (34%) or rhonchi (44%).
'Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis pipeline landscape is provided which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis treatment guidelines. The assessment part of the report embraces, in depth Non-Cystic Fibrosis Bronchiectasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Non-Cystic Fibrosis Bronchiectasis R&D. The therapies under development are focused on novel approaches to treat/improve Non-Cystic Fibrosis Bronchiectasis.
This segment of the Non-Cystic Fibrosis Bronchiectasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non-Cystic Fibrosis Bronchiectasis Emerging Drugs
- Brensocatib: Insmed Incorporated
- CSL787: CSL Behring
Further product details are provided in the report……..
Non-Cystic Fibrosis Bronchiectasis: Therapeutic Assessment
This segment of the report provides insights about the different Non-Cystic Fibrosis Bronchiectasis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Non-Cystic Fibrosis Bronchiectasis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Inhalation
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Non-Cystic Fibrosis Bronchiectasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Cystic Fibrosis Bronchiectasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Cystic Fibrosis Bronchiectasis drugs.
Non-Cystic Fibrosis Bronchiectasis Report Insights
- Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Non-Cystic Fibrosis Bronchiectasis drugs?
- How many Non-Cystic Fibrosis Bronchiectasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Cystic Fibrosis Bronchiectasis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Cystic Fibrosis Bronchiectasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Non-Cystic Fibrosis Bronchiectasis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Insmed Incorporated
- CSL Behring
- Boehringer Ingelheim
- Novartis
- SANTHERA PHARMACEUTICALS
- Brensocatib
- CSL787
- BI 1323495
- Tobramycin inhalation powder
- Lonodelestat
Introduction
Executive Summary
Non-Cystic Fibrosis Bronchiectasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Brensocatib: Insmed Incorporated
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tobramycin inhalation powder: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CSL787: CSL Behring
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Non-Cystic Fibrosis Bronchiectasis Key Companies
Non-Cystic Fibrosis Bronchiectasis Key Products
Non-Cystic Fibrosis Bronchiectasis- Unmet Needs
Non-Cystic Fibrosis Bronchiectasis- Market Drivers and Barriers
Non-Cystic Fibrosis Bronchiectasis- Future Perspectives and Conclusion
Non-Cystic Fibrosis Bronchiectasis Analyst Views
Non-Cystic Fibrosis Bronchiectasis Key Companies
Appendix
Executive Summary
Non-Cystic Fibrosis Bronchiectasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Brensocatib: Insmed Incorporated
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tobramycin inhalation powder: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CSL787: CSL Behring
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Non-Cystic Fibrosis Bronchiectasis Key Companies
Non-Cystic Fibrosis Bronchiectasis Key Products
Non-Cystic Fibrosis Bronchiectasis- Unmet Needs
Non-Cystic Fibrosis Bronchiectasis- Market Drivers and Barriers
Non-Cystic Fibrosis Bronchiectasis- Future Perspectives and Conclusion
Non-Cystic Fibrosis Bronchiectasis Analyst Views
Non-Cystic Fibrosis Bronchiectasis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Non-Cystic Fibrosis Bronchiectasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Non-Cystic Fibrosis Bronchiectasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Non-Cystic Fibrosis Bronchiectasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Non-Cystic Fibrosis Bronchiectasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
